دورية أكاديمية
Carbonic anhydrase IX: An atypical target for innovative therapies in cancer.
| العنوان: | Carbonic anhydrase IX: An atypical target for innovative therapies in cancer. |
|---|---|
| المؤلفون: | Ronca R; Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123 Brescia, Italy; Consorzio Interuniversitario per le Biotecnologie (CIB), Italy. Electronic address: roberto.ronca@unibs.it., Supuran CT; NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Florence 50019, Italy. Electronic address: claudiu.supuran@unifi.it. |
| المصدر: | Biochimica et biophysica acta. Reviews on cancer [Biochim Biophys Acta Rev Cancer] 2024 Jul; Vol. 1879 (4), pp. 189120. Date of Electronic Publication: 2024 May 25. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9806362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-2561 (Electronic) Linking ISSN: 0304419X NLM ISO Abbreviation: Biochim Biophys Acta Rev Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier |
| مواضيع طبية MeSH: | Carbonic Anhydrase IX*/antagonists & inhibitors , Carbonic Anhydrase IX*/metabolism , Neoplasms*/drug therapy , Neoplasms*/pathology , Neoplasms*/enzymology , Antigens, Neoplasm*/metabolism , Antigens, Neoplasm*/immunology , Carbonic Anhydrase Inhibitors*/therapeutic use , Carbonic Anhydrase Inhibitors*/pharmacology, Humans ; Molecular Targeted Therapy ; Animals |
| مستخلص: | Carbonic anhydrases (CAs), are metallo-enzymes implicated in several pathophysiological processes where tissue pH regulation is required. CA IX is a tumor-associated CA isoform induced by hypoxia and involved in the adaptation of tumor cells to acidosis. Indeed, several tumor-driving pathways can induce CA IX expression, and this in turn has been associated to cancer cells invasion and metastatic features as well as to induction of stem-like features, drug resistance and recurrence. After its functional and structural characterization CA IX targeting approaches have been developed to inhibit its activity in neoplastic tissues, and to date this field has seen an incredible acceleration in terms of therapeutic options and biological readouts. Small molecules inhibitors, hybrid/dual targeting drugs, targeting antibodies and adoptive (CAR-T based) cell therapy have been developed at preclinical level, whereas a sulfonamide CA IX inhibitor and an antibody entered Phase Ib/II clinical trials for the treatment and imaging of different solid tumors. Here recent advances on CA IX biology and pharmacology in cancer, and its therapeutic targeting will be discussed. Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Roberto Ronca reports financial support was provided by Italian Association for Cancer Research. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Cancer; Carbonic anhydrase IX; Imaging; Target therapy |
| المشرفين على المادة: | EC 4.2.1.1 (Carbonic Anhydrase IX) 0 (Antigens, Neoplasm) 0 (Carbonic Anhydrase Inhibitors) EC 4.2.1.1 (CA9 protein, human) |
| تواريخ الأحداث: | Date Created: 20240527 Date Completed: 20240614 Latest Revision: 20240618 |
| رمز التحديث: | 20240619 |
| DOI: | 10.1016/j.bbcan.2024.189120 |
| PMID: | 38801961 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1879-2561 |
|---|---|
| DOI: | 10.1016/j.bbcan.2024.189120 |